Oral Compositions Comprising Propolis

ABSTRACT

Oral compositions are provided that comprise a propolis extract; an oral care active compound chosen from: a cationic antibacterial agent, an anti-attachment agent, a biofilm disruption agent, and an anti-inflammatory agent; and a source of fluoride ions. Further, in certain embodiments, the oral composition comprises an anionic polymeric linear polycarboxylate. The oral composition can be in a form of a mouth rinse, a dentifrice, a confectionary, a medicament, or a film. Methods of making and using the oral compositions are also provided.

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. application Ser. No.11/611,701 filed Dec. 15, 2006, which claims benefit of U.S. ProvisionalPatent Application No. 60/752,617 filed Dec. 21, 2005, which isincorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Human periodontal diseases are inflammatory disorders that are theresult of complex interactions between periodontopathogens and thehost's immune system response. It is believed that there are twointerrelated aspects to the progression of periodontal disease; thefirst is the activation of the immune system of the host and the secondis the production of oxygen radicals and their related metabolites.Increased production of oxygen radicals may contribute to oxidativestress, which is believed to be involved in periodontal disease.

Gingivitis is the inflammation or infection of the gums and the alveolarbones that support the teeth. Gingivitis is generally believed to becaused by bacteria in the mouth (particularly the bacteria associatedwith plaque formation) and the inflammatory response triggered by thepresence of bacteria and the toxins formed as by-products from thebacteria. Periodontitis is a progressively worsened state of disease ascompared to gingivitis, where inflamed gums begin to recede from theteeth, thus forming pockets there between, which can ultimately resultin destruction of the bone and periodontal ligament. Chronic infectionand inflammation potentially results in the subsequent loss of teeth.

It is generally believed that the cellular components implicated bythese diseases and conditions include epithelial tissue, gingivalfibroblasts, and circulating leukocytes, all of which contribute to thehost response to pathogenic factors generated by the bacteria. Althoughthe bacterial infection is often the etiological event in many of theseoral diseases, the pathogenesis of the disease is mediated by the hostresponse.

Bacterial infection of the oral tissue increases the host's immunesystem response and diminishes the healing process by up-regulatinginflammatory mediators that can induce significant tissue damagesurrounding the foci of infection.

There is a need for oral care compositions that effectively reduce thedevelopment or progression of oral disease, preferably by having anactive ingredient that diminishes the effects of oral disease bypreventing or reducing multiple etiological factors that contribute toand/or exacerbate oral disease. Further, there is a need to stabilizeoral care actives in an oral composition, so that their functionalityand bioavailability as delivered to a subject in vivo is preserved andstabilized.

BRIEF SUMMARY OF THE INVENTION

In certain embodiments, the present invention is directed to an oralcomposition comprising:

-   -   a propolis extract;    -   an oral care active compound chosen from: a cationic        antibacterial agent, an anti-attachment agent, a biofilm        disruption agent or an anti-inflammatory agent; and    -   a source of fluoride ions.

In certain embodiments, the present invention is directed to a method ofmaking an oral composition comprising:

-   -   admixing one or more carrier ingredients to form a homogenous        mixture;    -   adding a fluoride ion source to the mixture;    -   adding at least one of: a cationic antibacterial agent, an        anti-attachment agent, a biofilm disruption agent or an        anti-inflammatory agent; and    -   adding a propolis extract to the homogeneous mixture at        temperatures of less than or equal to about 40° C. to form the        oral composition.

In certain embodiments, the present invention is directed to methods ofpreventing bacterial from forming a biofilm, suppressing an immunesystem recognition of an antigen on an oral surface of a mammal,reducing an immune system response, and suppressing production of one ormore mediators of inflammation on an oral surface, comprisingadministering and applying the compositions herein to the oral surface.In certain embodiments, the present invention is directed to methods ofmaintaining or increasing systemic health of a mammal comprisingapplying a composition according to claim 1 to the oral surfaces atleast once a day a period of time.

DETAILED DESCRIPTION OF THE INVENTION

As referred to herein, all references cited herein are herebyincorporated by reference in their entireties. Where there is a conflictbetween a definition in the present disclosure and that of a citedreference, the present disclosure controls. Furthermore, all percentagesexpressed are weight percentages.

In various embodiments, an oral composition is provided that comprisesan extract of propolis, and an oral care active compound chosen from: acationic antibacterial agent, an anti-attachment agent, a biofilmdisruption agent, an anti-inflammatory agent, or mixtures thereof. Insome embodiments, the active ingredient may comprise three or moreconstituents. For example, in certain embodiments the active ingredientcomprises a third constituent that comprises a source of fluoride ions.In other embodiments, the oral composition comprises an anionicpolymeric linear polycarboxylate, as will be described in more detailbelow.

The compositions of the present invention comprise a propolis extract.As referred to herein, the terms “propolis,” “propolis extract” or an“extract of propolis” refer to a composition that is obtained from asource produced by bees, which are generally classified in the familyApidae, preferably of the genus Apis. For example, suitable extractsinclude those isolated from a source generated by Apis mellifera(commonly known as the “honeybee”), including its various sub-species(Apis mellifera ssp.), such as Apis mellifera caucasica (the “Caucasianhoneybee” or the “western honeybee”). As referred to hereinafter, theterms “propolis,” “propolis extract” or an “extract of propolis”encompass all suitable resin products produced by species andsub-species of the family Apidae, as well as synthetic or semi-syntheticequivalents of such natural extracts or active components containedtherein.

It is reported that propolis contains numerous active compounds,including many classes of polyphenolic compounds, flavones, flavonones,phenolic acid, and esters. While these compounds are not entirelyunderstood or characterized, they are generally believed to vary basedupon the geographical location and where the bees are located.Generally, on a weight basis propolis contains about 45 to about 55%resins and balsams (including for example, flavonoids, phenolic acids,and esters); about 25 to about 35% waxes and fatty acids; about 10%essential oils; about 5% pollen (including proteins and protein-derivedamino acids); and about 5% of other organic compounds and minerals(including trace minerals, vitamins, ketones, lactones, quinones,steroids, benzoic acid and esters, and sugars); among other compounds.

In certain embodiments, the propolis extract comprises one or moreactive compounds that have been isolated from a propolis source. Thepropolis extract may include a complement of active compounds naturallyoccurring in the propolis source. A propolis extract of the presentinvention may include a form of the extract and at least one activecompound, for example two or more active compounds, or even a pluralityof active compounds derived from a propolis source. In certainembodiments, various propolis extracts can be provided in hydrophilic orlipophilic carriers, depending on the solvent used during extraction.The extracts may be in a liquid, paste, or dried powder form.

Certain microorganisms are known to accumulate and promote formation ofa dental plaque matrix (i.e., biofilm) on an oral surface, which in turnfacilitates formation of tartar, gingivitis, periodontitis, caries,candidiasis, and/or denture stomatitis, inter alia. In certainembodiments, the compositions of the present invention inhibit theaccumulation of such microorganisms. Propolis has been reported toinhibit the accumulation of microorganisms such as lactobacilli,actinomyces, leptotrichiae, non-β-hemolytic streptococci, enterococci,miscellaneous gram-positive cocci, neisseriae, diphtheroid bacilli,fusiform bacilli, bacteroides, spirochetes, yeasts (Candida), andcombinations thereof. In accordance with various embodiments, thepropolis extract may provide one or more of the following oral carebenefits: antibacterial, anti-microbial, anti-inflammatory,anti-oxidant, anti-caries, antiplaque and anti-tartar.

As used herein, “extracting” or “extraction” of a solid or liquidmaterial refers to contacting the material with an appropriate solventto remove the substance(s) desired to be extracted from the material.Where the material is solid, it is preferably cleaned of debris andexcess wax, and then broken into small pieces, crushed, or ground to apowder prior to contacting it with the solvent. Such an extraction maybe carried out by conventional means known to one of skill in the art;for example, by using an extraction apparatus, such as a Soxhletapparatus, which retains the solid material in a holder and allows thesolvent to flow through the material; or by blending the solvent andmaterial together and then separating the liquid and solid phases or twoimmiscible liquid phases, such as by filtration or by settling anddecanting. It is preferred that natural extract active ingredients usedin oral care compositions are of reproducible, stable quality and havemicrobiological safety.

Propolis extract may be prepared by extracting the solid propolismaterial using an appropriate solvent. Selection of the extractionsolvent is typically dictated by the final use of the extract and ontechnical feasibility. Preferred non-limiting solvents for extractioninclude monohydric solvents, i.e., alcohols such as methanol, andethanol; polyhydric solvents, such as propylene glycol; acetic acid;sodium hydroxide (preferably in combination with water); water; oils;and the like. While other solvents can also be used for extraction ofpropolis, such as ether, acetone, benzene and ammonia, they aregenerally not considered suitable for use in oral care compositions.

Other methods of extraction include steam distillation or supercriticalfluid extraction. In one embodiment, the propolis extract is isolated bysupercritical fluid extraction (SFE), such as SFE using carbon dioxide(CO₂), steam distillation or using vehicles such as sunflower or avocadooils. Methods of preparing a propolis extract can include those known inthe art, such as, for example, those described in U.S. Pat. Nos.6,153,227 and 6,153,228 to Shibuya et al. and 5,922,324 to Aga et al.

Generally, one part of propolis (dry basis) is extracted with about 1 toabout 50 parts of solvent, preferably from about 10 parts to about 40parts of solvent using an extraction apparatus where the solvent iscontacted with the propolis matter to obtain a concentrated extract. Theextract can be in the form of a paste, which is then optionallysubjected to one or more additional extraction steps with differentsolvents to further concentrate the originally obtained paste over anextended period of time, for example about 6 hours to about 2 days, orfor about 1 day. The propolis may be extracted with a mixture of apolyhydric compound and water. For example, the extraction solvent maybe a mixture of water to propylene glycol, in a ratio of about 1:2 toabout 2:1. In certain embodiments, the first constituent comprisingpropolis extract comprises one or more active compounds derived from apropolis source, at from about 1 to about 75% by weight of the extract.In certain embodiments, the propolis extract product is in a liquidform. Thus, the first constituent comprises about 1 to about 5% byweight of active compounds derived from the propolis source, about 94 toabout 99% solvent and optionally about 0.1 to about 1% other compounds,such as preservatives and impurities.

In various embodiments, the propolis extract is present in the oralcomposition of about 0.0001 to about 3% by weight, less than about 1% byweight, about 0.0002 to about 1% by weight or about 0.0003 to about 0.5%by weight.

As described above, the oral compositions of the present inventionfurther comprise an oral care active compound chosen from: a cationicantibacterial agent, an anti-attachment agent, a biofilm disruptionagent, an anti-inflammatory agent, or mixtures thereof. As appreciatedby one of skill in the art, an oral care active compound may fall intoone or more of these classifications, as it may have multiple mechanismsand/or effects, and may not be limited to a single function orclassification. In certain embodiments, the oral care active compoundhas a functionality or mechanism for preventing and/or treating an oralcare disease, where the mechanism complements and/or supplements themechanism provided by the propolis extract described above. In addition,for the present purposes, the terms “cationic antibacterial agent,”“anti-attachment agent,” “biofilm disruption agent” and“anti-inflammatory agent” refer to compositions other than propolisextracts.

In certain embodiments, the oral care active compound is a cationicantibacterial agent that is highly effective in oral care compositionsfor use in certain embodiments. Suitable cationic antibacterial agentsfor use in oral compositions include, for example:

(i) quaternary ammonium compounds, such as those in which one or two ofthe substituents on the quaternary nitrogen has from 8 to 20, preferablyfrom 10 to 18 carbon atoms and is preferably an alkyl group, which mayoptionally be interrupted by an amide, ester, oxygen, sulfur, orheterocyclic ring, while the remaining substituents have a lower numberof carbon atoms, for instance from 1 to 7, and are preferably alkyl, forinstance methyl or ethyl, or benzyl. Examples of such compounds includebenzalkonium chloride, dodecyl trimethyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, hexadecyltrimethyl ammonium bromide,benzethonium chloride (diisobutyl phenoxyethoxyethyl dimethyl benzylammonium chloride) and methyl benzethonium chloride;

-   -   (ii) pyridinium and isoquinolinium compounds, including        hexadecylpyridinium chloride and alkyl isoquinolinium bromides;    -   (iii) pyrimidine derivatives such as hexetidine        (5-amino-1,3-bis(2-ethylhexyl)-5-methyl-hexahydropyrimidine);    -   (iv) amidine derivatives such as hexamidine isethionate        (4,4′-diamidino-αω-diphenoxy-hexane isethionate);    -   (v) bispyridine derivatives such as octenidine dihydrochloride        (N,N′ [1,10-decanediyldi-1        (4H)-pyridinyl-4-ylidene]-bis(1-octanamine) dihydrochloride);    -   (vi) guanides, for example, mono-biguanides such as        p-chlorobenzyl-biguanide and        N′(4-chlorobenzyl)-N″-(2,4-dichlorobenzyl) biguanide,        poly(biguanides) such as polyhexamethylene biguanide        hydrochloride, and bis-biguanides of the general formula (1):

in which A and A¹ each represent (i) a phenyl group optionallysubstituted by (C₁₋₄) alkyl, (C₁₋₄) alkoxy, nitro, or halogen, (ii) a(C₁₋₁₂) alkyl group, or (iii) a (C₄₋₁₂) acyclic group; X and X¹ eachrepresent (C₁₋₃) alkylene; R and R¹ each represent hydrogen, (C₁₋₁₂)alkyl, or aryl (C₁₋₆) alkyl; Z and Z1 are each 0 or 1; n is an integerfrom 2 to 12; and the polymethylene chain (CH₂)_(n) may optionally beinterrupted by oxygen or sulfur or an aromatic (for instance, phenyl ornaphthyl) nucleus; and orally acceptable acid addition salts thereof;examples of such bis-biguanides include chlorhexidine and alexidine.Suitable acid addition salts of the bis-biguanides of general formula(1) include the diacetate, the dihydrochloride and the digluconate.Suitable acid addition salts of chlorhexidine include the digluconate,diformate, diacetate, dipropionate, dihydrochloride, dihydroiodide,dilactate, dinitrate, sulphate, and tartrate salts. Suitable acidaddition salts of alexidine include the dihydrofluoride and thedihydrochloride salts; and

-   -   vii) N^(α)-acyl amino acid alkyl esters and salts generally        represented by the formula (2) below:

where R¹ is an alkyl chain of 1 to 8 carbon atoms, preferably from 1 to3 carbon atoms, and most preferably 3 carbon atoms; R² is an alkyl chainof 6 to 30 carbon atoms, preferably from 10 to 12 carbon atoms, andmixtures thereof; and X is an anion. In various embodiments, the R²COmoiety comprises a natural fatty acid residue such as a natural fattyacid chosen from coconut oil fatty acid, tallow fatty acid residue, or amono-fatty acid residue such as lauroyl (C₁₂), myristyl (C₁₄), stearoyl(C₁₈) fatty acid residues, or mixtures thereof. In certain embodiments,the R²CO moiety comprises a lauroyl fatty acid residue.

X may be any counter-anion that provides a reasonable degree ofsolubility in water (preferably at least about 1 g in 1 L of water).Examples of X counter anions that form antibacterial ester salts of theabove identified formula, include inorganic acid salts, such as thosecomprising halogen atoms (e.g., chloride or bromide) or dihydrogenphosphate, or an organic salt such as acetate, tautarate, citrate, orpyrrolidone-carboxylate (PCA).

Examples of useful antibacterial esters of the above-identified formulawherein n equals 3 include: N′-cocoyl-L-arginine methyl ester,N^(α)-cocoyl-L-arginine ethyl ester, N^(α)-cocoyl-L-arginine propylester, N^(α)-stearoyl-L-arginine methyl ester, N^(α)-stearoyl-L-arginineethyl ester hydrochloride. In one embodiment, the arginine derivativecompound is the hydrogen chloride salt of ethyl lauroyl arginine (ELAH).It should be noted that the N^(α)-acyl amino acid alkyl ester salts aregenerally classified as cationic antibacterial agents. However, suchcompounds also tend to exhibit anti-attachment and other properties thatprevent the formation of plaque on oral surfaces, which will bedescribed in more detail below.

Thus, in certain embodiments, the cationic antibacterial agent is chosenfrom: benzethonium chloride, octenidine, hexetidine, hexamidine, cetylpyridinium chloride (CPC), alexidine, N^(α)-acyl amino acid alkyl estersalts (such as ethyl lauroyl arginine ester hydrochloride (ELAH)), andmixtures thereof.

In various embodiments, the cationic antibacterial agent is present inthe oral compositions in an amount of about 0.001 to about 3%, about0.005 to about 2% and about 0.01 to about 1%.

In other embodiments, the oral care active compound is ananti-attachment agent. While not limiting as to the present invention,oral care active compounds are generally believed to operate by either(or both) of two predominant anti-attachment mechanisms. Biofilms (alsoreferred to as pellicle) are a matrix formed on an oral surface,typically on a hard tissue surface, comprising bacteria (generally about60-70% of the biomatrix), bacterial extracellular byproducts, proteins,lipids, and glycolipids. The term “oral surface” encompasses hard andsoft tissues within the oral cavity. Hard tissues include the teeth,periodontal support, and the like. Soft tissues comprise gums, thetongue, surfaces of the buccal cavity and the like. The oralcompositions of the various embodiments can be used in a mammaliansubject, which includes, inter alia, humans and other warm bloodedhigher level vertebrate animals, such as felines and canines.

Early stages of biofilm formation include an initial bacteria layer thatattaches to an oral surface, generally believed to be attached byligands or adhesins on the bacterial cell wall that interact withreceptors on an oral surface. It is believed that the bacterial cellsattach to the salivary glycoproteins on the oral surface, e.g., enamel.The bacteria appear to form a stronger attachment by generatingextracellular glucan polymers to adhere to the oral surface. Thebacteria then grow and divide, forming a dense layer on the oralsurface. After a specific density is reached, it is believed that thebacteria reorganize and begin to form pillars and irregular surfacestructures. Further, the biofilm matrix is believed to have a complexassociation of multi-layered and diverse species that form cell clustersattached to the anchoring bacteria of the first layer.

Thus, anti-attachment agents can interact with an oral surface to form aprotective layer, such that the bacteria and biofilm components cannotadhere to the oral surface, thereby preventing an initial anchoringlayer from forming on the oral surface. Such an anti-attachment agentmay substantially cover an oral surface, and prevent attachment of thebacteria and other components of the biofilm matrix. In a secondmechanism of anti-attachment agents, the anti-attachment agent interactswith the bacteria itself to disable it from attaching to the oralsurface, likely by interacting with the adhesins, ligands, or othermoieties on the surface of the bacteria that would ordinarily facilitatea linkage with a receptor or other moiety at the oral surface. Forexample, certain active ingredients may interfere with a glucosyltransferase enzyme on bacterial outer cell walls, thereby preventingconversion of various sugars to glucans that would otherwise form theextracellular anchoring matrix for the biofilm.

While not limiting as to the present invention, it is believed that insome embodiments where the oral care active compound is selected tocomprise an N^(α)-acyl amino acid alkyl ester salts, such as ethyllauroyl arginate hydrochloride (ELAH), the active ingredients functionas an anti-attachment active ingredient, in addition to a cationicantimicrobial ingredient. ELAH appears to alter the surface energy ofhard tissues, such as enamel (by reducing the surface energy), and inturn, prevents adherence and attachment of microorganisms that mayotherwise form a plaque biofilm on the tooth surface. ELAH appears tohave substantivity on the tooth surface, such that it remains attachedfor a sufficient period of time to effectively prevent microorganismsfrom adhering to the tooth surface, thereby preventing or reducingbiofilm formation.

In various embodiments, such an anti-attachment effect may be obtainedat low concentrations, potentially below the Minimum InhibitoryConcentration (MIC) for ELAH. In various embodiments, the application ofthe ELAH as an active ingredient promotes longer and more effectiveanti-plaque benefits at lower concentrations in comparison with manyother antimicrobial ingredients that are washed away in the aqueous oralcavity. Further, without limiting the present invention, it ishypothesized that ELAH may interfere with the metabolism ofmicroorganisms in the biofilm, perhaps by arginine regulation, and inthis manner contribute to the anti-microbial, anti-plaque,anti-gingivitis, and anti-periodontitis efficacy of the activeingredient in oral compositions (thus also performing as a biofilmdisruption agent).

In various embodiments, the anti-attachment agent is present in the oralcompositions in an amount of about 0.001 to about 3%, about 0.005 toabout 2% and about 0.01 to about 1%.

In some embodiments, the oral care active compound is a biofilmdisruption agent. A biofilm disruption agent is a compound that preventsformation of and/or attacks a biofilm already formed on an oral surface.

Enzymes have conventionally been selected as biofilm disruption agents,based upon the ability of various enzymes to hydrolyze proteins, starchand lipids, which form a part of a biofilm matrix. In certainembodiments, such enzymes include protease enzymes, such as cysteineproteases. In certain embodiments, the biofilm disruption agent is anenzyme chosen from: papain, ficin, krillase or mixtures thereof.

Papain is obtained from the latex of the green fruit and leaves ofCarica papaya. Papain hydrolyzes polypeptides, more specifically,cleaving the carboxy terminus of arginine, lysine, glutamine, tyrosine,glycine, histidine (adjacent to phenylalanine) yielding peptides oflower molecular weight. Ficin is obtained by drying and filtering thelatex from the Ficus species (tropical fig trees Ficus glabrata).Krillase is extracted from Antarctic krill (Euphausia superba). Itconsists of endo- and exo-peptidases, which include four serineproteases and four carboxyopeptidases.

Other enzymes are also suitable for inclusion in oral compositions asplaque disruption agents. One selected enzyme that may be formulated incombination with a protease enzyme is the aforesaid glucoamylase.Glucoamylase is a saccharifying glucoamylase of Aspergillus niger origincultivated by fermentation. This enzyme can hydrolyze both the α-D-1,6glucosidic branch points and the α-1,4 glucosidic bonds of glucosyloligosaccharides. Additional useful are α and β-amylase, dextranase andmutanase.

Other suitable enzymes for use as a plaque disruption oral care activecompound include lysozyme, derived from egg white. The enzyme canexhibit antibacterial properties by facilitating the hydrolysis ofbacterial cell walls cleaving the glycosidic bond between carbon number1 of N-acetylmuramic acid and carbon number 4 of N-acetyl-D-glucosamine.In vivo, these two carbohydrates are polymerized to form the cell wallpolysaccharide. Additionally, pectinase, an enzyme that is present inmost plants, may facilitate the hydrolysis of the polysaccharide pectininto sugars and galacturonic acid, thus contributing to degradation ofbacteria and other microorganisms.

Other useful enzymes include lipases such as plant lipase, gastriclipase, pancreatic lipase, tannase lysozyme, serine proteases,bromelain, chymotrypsin, alcalase, amalysecs, lactoferrin, gingipains,glucose oxidase, elastases and/or cellusases. Other exemplary oral carebiofilm disruption agents include synthetic histatin, furanone, andderivatives and mixtures of any of the above.

In various embodiments, the biofilm disruption agent is present in theoral compositions in an amount of about 0.001 to about 3%, about 0.005to about 2% and about 0.01 to about 1%.

In certain embodiments, the oral care active compound is ananti-inflammatory agent. Suitable anti-inflammatory agents includecytokines and prostaglandins. The suppression of one or more of theabove described proinflammatory mediators prevents and/or treats tissuedamage and/or tissue loss when the tissue is inflamed. Thus, oral careactive compounds that serve as anti-inflammatory agents to suppress oneor more mediators of inflammation are useful for oral compositions.

Exemplary useful anti-inflammatory agents can include those that preventthe accumulation of inflammatory mediators derived from arachidonic acidpathway that is triggered by immune system detection of an antigen. Oneclass of mediators that modulate for inflammatory response arearachidonic acid metabolites, namely prostaglandins, leukotrienes, andthromboxanes, which are produced through the cyclooxygenase orlipoxygenase enzyme pathways. These metabolites have been implicated asthe prime mediators in gingivitis, periodontitis, osteomyelitis andother inflammatory diseases. For example, such anti-inflammatory agentsthat prevent the accumulation of inflammatory mediators from thearachidonic acid pathway, include non-steroidal anti-inflammatory drugs(NSAIDs). Examples of useful NSAID anti-inflammatory agents includeindomethicin, flurbiprofen, ketoprofen, ibuprofen, naproxen,meclofenamic acid or mixtures thereof.

In certain embodiments, the anti-inflammatory agent is capable ofsuppressing immune system recognition of one or more antigens producedby pathogens on an oral surface. For example, gram-negative bacteriahave endotoxins, generally known as lipopolysaccharide (LPS) components,which are embedded within the outer membrane of the cell wall. The LPSof the bacterial cells serve as antigens that are detected by variouscells within the immune system. The recognition of the LPS antigens byimmune system cells, such as by CD-14 receptors on monocytes andmacrophages, will typically result in an immune system response thatincludes production of cytokines, activation of the cascade complement(e.g., histamine release resulting in vasodilation and neutrophilchemotaxis), and activation of the coagulation cascade. Certain usefulanti-inflammatory compounds may prevent an immune system fromrecognizing of one or more antigens present in the oral cavity, such asLPS on the cell walls of gram-negative bacteria. Such anti-inflammatorydrugs are believed to interface with antigen in such a manner that themicrobe/bacteria is no longer recognized by the receptors of certaincells of the immune system (effectively cloaking it from immune systemdetection) and thereby suppressing an immune system response.

Likewise, in another mechanism for oral care anti-inflammatory agents,the anti-inflammatory agent serves to reduce or scavenge one or morereactive oxide species within the oral cavity. Reactive oxygen species(ROS) are typically highly reactive products produced during variousbiochemical processes, and include superoxide anions (O₂ ⁻ ), hydrogenperoxide (H₂O₂), and hydroxyl radicals (.OH). The formation of ROS canoccur as part of many cellular processes including mitochondrialrespiration, immune cell responses, cell injury, heat, radiation of manyorigins, from metabolism of drugs and other chemicals. ROS are thoughtto be involved in almost all disease processes, as well as in the ageingprocess. Increased ROS formation under pathological conditions isbelieved to cause cellular damage through the action of these highlyreactive molecules by crosslinking proteins, mutagenizing DNA, andperoxidizing lipids.

Examples of active oral compounds that are anti-inflammatory agents thatserve to reduce one or more ROS in the oral cavity, include oral careactive compounds comprising at least one flavonoid compound. Flavonoidsare generally described in are a class of compounds generally found inplants that have the same general structure and include compounds asflavones, flavans, flavonols, dihydroflanonols, flavonones, andderivatives thereof. In certain embodiments, the oral careanti-inflammatory agents comprise free-B-ring flavonoid compounds and/orflavans, which include flavanols. Compositions comprising free-B-ringflavonoids have been shown to inhibit activity of the cyclooxygenaseenzyme COX-2, for example. Examples of suitable anti-inflammatory agentsinclude those extracts and compounds derived from Scutellariabaicalensis, which contains significant amounts of free-B-ringflavonoids, including baicalein, baicalin, wogonin, and baicalenoside. Adescription of useful oral care anti-inflammatory agents comprisingfree-B-ring flavonoids may be found in U.S. Patent Application60/639,329 to Trivedi et al. filed Dec. 22, 2004.

Certain oral care active ingredient anti-inflammatory agents include amixture of at least one free-B-ring flavonoid and at least one flavan.Exemplary sources of flavans can be found in extracts derived fromplants of the family Fabaceae, the subfamily Mimosoide, the genusAcacia. For example, suitable flavans can be isolated from the plantAcacia catechu. Catechin is an example of a flavan that is foundextensively in Acacia, that exhibits, both alone and in conjunction withflavonoids, antiviral and antioxidant activity, as well as an ability toinhibit activity of both the COX-1 and COX-2 enzymes. A mixture of atleast one free-B-ring flavonoid and a flavan is also suitable for use asan anti-inflammatory agent. A description of useful oral careanti-inflammatory agents comprising free-B-ring flavonoids and at leastone flavan is found in U.S. Patent Application 60/639,331 to Xu et al.filed Dec. 22, 2004.

A commercially available oral care active comprising at least onefree-B-ring flavonoid and at least one flavan is UNIVESTIN®, which isisolated from plants of the genus Scutelleria, and manufactured byUnigen Pharmaceuticals, Inc. (Superior, Col., USA). A description ofUNIVESTIN® can be found in, for example, U.S. Patent ApplicationPublication 2003/0216481 to Jia. UNIVESTIN® inhibits specific enzymesthat catalyze oral inflammatory pathways, such as and for example, theCOX-1, COX-2, and 5-LO enzymes.

Another suitable anti-inflammatory agent is oregano extract. As referredto hereinafter, “oregano” encompasses all suitable species andsub-species of the genus Origanum; for example, Origanum vulgare(commonly known as “oregano,”, “wild oregano” or “wild marjoram”),including its sub-species (Origanum vulgare ssp.), Origanum onites(commonly known as “Italian oregano” or “pot marjoram”), Origanummajorana (commonly known as “marjoram” or “sweet marjoram”) and Origanumheracleoticum. Origanum vulgare subspecies include O. vulgare ssp.vulgare, O. vulgare ssp. viride, and O. vulgare ssp. hirtum (commonlyknown as “Greek oregano” or “Wild oregano”). Useful oral care activeingredients comprising oregano extract are discussed in U.S. patentapplication Ser. No. 11/256,788, Worrell et al. filed Oct. 24, 2005. Yetanother suitable anti-inflammatory agent is magnolia extract, derivedfrom plants in the Magnoliaceae family, such as Magnolia officinalis,that typically contains magnolol, honokiol, tetrahydromagnolol, andtetrahydrohonokiol, as described in U.S. Patent Application 60/640,161to Gaffar et al. filed Dec. 29, 2004.

In various embodiments, the anti-inflammatory agent is present in theoral compositions in an amount of about 0.001 to about 3%, about 0.005to about 2% and about 0.01 to about 1%.

In certain embodiments, a composition of the present invention furthercomprises a source of fluoride ions or fluorine-providing component, asanti-caries and/or anti-tartar agents, in an amount sufficient to supplyabout 25 ppm to about 5,000 ppm of fluoride ions. Examples of usefulfluoride ion sources include inorganic fluoride salts, such as solublealkali metal salts. For example, in certain embodiments, the fluoridesource in the composition may be sodium fluoride, potassium fluoride,sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluorides, including olaflur(N′-octadecyltrimethylenediamine-N,N,N-tris(2-ethanol)-dihydrofluoride),as well as tin fluorides, such as stannous fluoride.

Synthetic anionic linear polycarboxylates are efficacy enhancing agentsfor optional use in oral compositions having certain active ingredients,including antibacterial, anti-tartar or other active agents within theoral composition. Such anionic polycarboxylates are generally employedin the form of their free acids, or preferably partially neutralized ormore preferably fully neutralized water soluble alkali metal (e.g.,potassium and preferably sodium) or ammonium salts. The terms“synthetic” and “linear” exclude known thickening or gelling agentscomprising carboxymethylcellulose and other derivatives of cellulose andnatural gums, nor carbopols having reduced solubility due tocross-linkages.

Preferred copolymers are 1:4 to 4:1 copolymers of maleic anhydride oracid with another polymerizable ethylenically unsaturated monomer,preferably methyl vinyl ether (methoxyethylene) having a molecularweight (M.W.) of about 30,000 to about 1,000,000. One preferablecopolymer is methylvinylether/maleic anhydride. Examples of thesecopolymers are available from ISP Corporation under the trade nameGANTREZ®, e.g., AN 139 (M.W. 1,100,000), AN 119 (M.W. 200,000); S-97Pharmaceutical Grade (M.W. 1,500,000), AN 169 (M.W. 2,000,000), and AN179 (M.W. 2,400,000); wherein the preferred copolymer is S-97Pharmaceutical Grade (M.W. 1,500,000). In various embodiments where asynthetic anionic polycarboxylate is included in the oral composition,it is present in amounts of about 0.001 to about 5%, about 0.01 to about4%, about 0.1 to about 3.5% or about 1 to about 3% of the oral carecomposition.

Additional optional oral care compounds that can be included in the oralcomposition include, for example, additional antibacterial agents,whitening agents, additional anti-caries and tartar control agents notalready discussed above, periodontal actives, abrasives, breathfreshening agents, malodor control agents, tooth desensitizers, salivarystimulants and combinations thereof. Specifically, a non-limiting listof useful additional oral care compounds includes non-ionicantibacterial agents, including phenolic and bisphenolic compounds, suchas, halogenated diphenyl ethers, including triclosan(2,4,4′-trichloro-2′-hydroxy-diphenylether, triclocarban(3,4,4-trichlorocarbanilide), as well as 2-phenoxyethanol, benzoateesters, and carbanilides. Useful anti-tartar agents include tin ionsources, such as such as stannous fluoride, stannous chloride, andstannous pyrophosphate, and/or zinc ion sources, such as zinc chloride,zinc citrate and zinc gluconate.

The oral compositions may be provided in an orally acceptable carrier orvehicle. The carrier can be a liquid, semi-solid, or solid phase, in theform of a mouth rinse, dentifrice (including toothpastes, toothpowders,and prophylaxis pastes), confectionaries (including lozenges, and gum),medicament, film, or any other form known to one of skill in the art.Selection of specific carrier components is dependent on the desiredproduct form.

Conventional ingredients that can be used to form the carriers listedabove are known to the skilled artisan. As recognized by one of skill inthe art, the oral compositions optionally include other materials inaddition to those components previously described, including forexample, surface active agents, emulsifiers, and foam modulators,viscosity modifiers and thickeners, humectants, diluents, additional pHmodifying agents, emollients, moisturizers, mouth feel agents,sweetening agents, flavor agents, colorants, preservatives, solvents,such as water and combinations thereof. Any given material may servemultiple purposes within two or more of such categories of materials.Preferably, such carrier materials are selected for compatibility andstability with all of the constituents of the active ingredient,including propolis extract and the one or more oral care activecompounds selected for the oral composition.

Typical useful surface active agents are disclosed in the patentreferences referenced and discussed above, including in U.S. Pat. No.4,894,220 and U.S. patent application Ser. No. 11/256,788. Surfaceactive agents generally are an important aspect of the oral composition,as they can function as surfactants, emulsifiers foam modulators, and/oractive ingredient dispersion agents. Thus, their selection forcompatibility with the active ingredient constituents is important. Forexample, in embodiments where the oral composition has an activeingredient comprising a cationic antibacterial agent, it is preferredthat the carrier comprises surfactants that are not strongly anionic, assuch anionic compounds can bind to the cationic active ingredientpotentially reducing its bioavailability.

Suitable surface active agents are those that are reasonably stable andfoam throughout a wide pH range. These compounds are known in the art,and include non-soap anionic (e.g., sodium lauryl sulfate (SLS),N-myristoyl, and N-palmitoyl sarcosine), nonionic (e.g., Polysorbate 20(polyoxyethylene 20 sorbitan monolaurate, TWEEN® 20) and Polysorbate 80(polyoxyethylene 20 sorbitan mono-oleate, TWEEN® 80), Poloxamer 407,available under the trade name Pluronic® F127 from BASF Corporation),cationic, zwitterionic (e.g., cocoamidopropyl betaine and lauramidopropyl betaine), and amphoteric organic synthetic detergents. Inembodiments where the active ingredient comprises a cationic compound,the surface active agent may be chosen from: non-ionic surfactants,cationic surfactants, betaine surfactants, amphoteric surfactants ormixtures thereof. In various embodiments, one or more surface activeagents are present in the oral composition in an amount of about 0.001%to about 5%, or about 0.5% to about 2.5%.

In embodiments where the oral composition is in the form of amouthrinse, an exemplary carrier is substantially liquid. The term“mouthrinse” includes mouth washes, sprays, rinses, and the like. Insuch a preparation the orally acceptable carrier typically has anaqueous phase comprising either water, or a water and alcohol mixture.Further, in various embodiments, the oral carrier typically has ahumectant, surfactant, and/or a pH buffering agent.

Depending on the extraction process and the concentration of thepropolis extract used in the oral composition, it is possible that thesmell and/or flavor of propolis extract is not aesthetically pleasing tosome consumers. Thus it is desirable to formulate an oral compositionthat comprises components that reduce any adverse perception of thepropolis extract. This can be accomplished by including relativelystrong flavoring and/or sweetening agents into the oral composition.Further, in some embodiments, the flavoring agent may provide and/orenhance the flavors associated with bee products. Exemplary flavoringsubstances include those known to a skilled artisan, and are present incertain embodiments at a concentration of about 0.05% by weight to about5% by weight.

In embodiments where an oral composition is in the form of aconfectionary, an exemplary carrier is substantially solid orsemi-solid. Confectionary carriers are known in the art. For a lozenge,the carrier typically comprises a lozenge base material (for example,comprising a non-cariogenic polyol and/or starch/sugar derivative), anemulsifier, a lubricant, a flavoring agent, a thickener, and optionallya coating material. Chewing gum carriers generally have a chewing gumbase, one or more plasticizing agents, a sweetening agent, and aflavoring agent.

In embodiments where an oral composition is in the form of a film, anexemplary carrier is substantially solid or semi-solid. Generally, suchfilm carriers comprise a water soluble or dispersible film formingagent, such as a hydrophilic polymer. Optionally, the film carrier mayalso comprise hydrophobic film forming polymers, either as a removablebacking layer, or mixed with a hydrophilic film forming polymer. Filmcarriers optionally comprise additional ingredients such asplasticizers, surface active agents, fillers, bulking agents, andviscosity modifying agents.

In embodiments where an oral composition is in the form of a dentifrice,an exemplary carrier is substantially semi-solid or a solid. Dentifricestypically contain surface active agents, humectants, viscosity modifyingagents and/or thickeners, abrasives, solvents, such as water, flavoringagents, and sweetening agents.

In certain embodiments, an oral composition is in the form of amedicament, such as a non-abrasive gel or ointment that can be appliedto the gingival sulcus or margin and used in conjunction with wounddressings, gauze, films, and the like. Such gels may include bothaqueous and non-aqueous gels. Aqueous gels generally comprise a polymerbase, a thickener, a humectant, a flavoring agent, a sweetening agent,and a solvent, typically including water.

In various embodiments, an oral composition is provided within a singlecomponent or phase. In other embodiments, the oral composition includesboth a first and a second component that are separately maintained.Maintaining the components separately requires only that the componentsare maintained in such a way as to substantially prevent the interactionof one component of the oral composition with another component of theoral composition. Typically, a dual component oral composition isemployed where there are one or more incompatible ingredients includedin the oral composition. For example, if the active ingredient comprisesa second constituent that comprises a cationic antibacterial active, itis advantageous to maintain the cationic compound separately fromstrongly anionic components, such as anionic surface active ingredients.The separation of components can be accomplished through any means knownin the art and includes chemical, physical, and mechanical means ofseparation or any combination of these. For example, the first andsecond components may be combined but certain components may beseparately maintained by wrapping or encapsulating one or both in afilm, coating, capsule, micelle, etc.

In various embodiments, a method promotes oral health in an oral cavityand treats plaque on an oral surface of a mammalian subject. In someembodiments, a method of providing one or more oral health benefits toan oral cavity of a mammalian subject comprises preparing an oralcomposition according to any of the various embodiments described above,where an active ingredient comprises a propolis extract, an oral careactive compound and a source of fluoride ions. Various embodiments aredirected to a method of preventing bacteria from forming a biofilm on anoral surface, a method of suppressing an immune system recognition of anantigen on an oral surface of a mammal, a method of reducing an immunesystem response, a method of suppressing production of one or moremediators of inflammation on an oral surface. In these embodiments, theprepared oral composition is contacted with an oral surface. The oralcomposition containing the active ingredient comprising a propolisextract may provide one or more oral health benefits, such asanti-gingivitis, anti-periodontitis, anti-caries, anti-tartar,anti-inflammatory, analgesic, anti-aging, and breath freshening.

Thus, any of the various embodiments of the oral care compositiondescribed above may be contacted with or applied regularly to an oralsurface for at least once a day for a period of time. As used herein,“period of time” may refer to, for example, once a day, multiple days ina week, on a long-term daily or weekly basis, or even for the balance ofa lifetime.

Various embodiments herein relate to methods of making oralcompositions. As propolis extract is a natural product, it containssensitive compounds that can be potentially denatured or damaged by heattreatment. Thus, certain embodiments are directed to methods of makingan oral composition comprising admixing one or more carrier ingredientsto form a homogenous mixture, and adding a propolis extract to thehomogenous mixture at temperatures of less than about 40° C. to form theoral composition. In various embodiments the propolis extract may beadded into the oral composition at ambient temperatures, e.g., less thanabout 30° C., or less than or equal to about 25° C.

The oral compositions may be prepared by suitably admixing theingredients. For instance, in the preparation of a mouthrinse, thepropolis extract may be dispersed in a flavor oil or an alcohol and thenadded to a mixture of humectants, surfactants, and water. The resultingrinse product is then packaged.

Dentifrices are typically prepared by adding various salts (includingfluoride salts, when included in the composition), and sweeteners (e.g.,saccharin), and any water-soluble oral care active ingredient compoundsto water, where it is mixed. Into another container, all humectants,gums, and polymers may be added together. The water based mixturedescribed above is added to the container with the humectants, gums, andpolymers. The combined ingredients are optionally heated to atemperature of greater than about 40° C., for example from about 60° C.to about 70° C., to disperse the gums and polymers. The heated mixtureis then cooled to less than approximately 38° C. (about 100° F.). Themixture is then combined with abrasives, where it is mixed at high speedunder a vacuum for about 15 to about 20 minutes. The propolis extract isadmixed into flavor oil (and/or alcohol), as are any lipophilic oralcare active ingredients. This mixture is admixed to the water basedmixture above, where it is mixed under high speed and vacuum untilsufficiently dispersed. The surfactant(s) are added and the mixture isagain mixed to disperse.

In certain embodiments, a method of making an oral composition comprisesadding an additional oral care active ingredient to the one or morecarrier ingredients prior to admixing. In other embodiments, anadditional oral care active ingredient is added with the propolisextract to the homogenous mixture. Whether additional oral care activecompounds are added to the one or more carrier ingredients prior toadmixing them to form a homogenous mixture, or added to the mixture withthe propolis extract after admixing, is dependent upon the nature of theadditional active ingredient (for example, whether it can withstandheating to greater than or equal to about 40° C. and whether it ishydrophobic, hydrophilic, anionic, cationic, or non-ionic). One of skillin the art can readily determine the appropriate point in the method ofmaking the oral composition to add the active ingredients, based uponthese considerations. For example, in certain embodiments, where theadditional constituent in the oral care active ingredient comprises asource of fluoride ions, the fluoride ion source can be added to the oneor more carrier ingredients prior to the admixing because it is solublein water.

The oral composition can be incorporated into confectionary and tropes.Such methods of forming confectionary (e.g., gum) or tropes (e.g.,lozenges) are known by one of skill in the art, and can be prepared by,for example, stirring the propolis extract and other oral care activecompound(s) into a warm gum base or coating the outer surface of a gumbase (for example, jelutone, rubber latex, vinylite resins, inter alia),desirably with conventional plasticizers or softeners, sugar or othersweeteners or carbohydrates such as glucose, sorbitol and the like. Incertain embodiments, the propolis extract is added to the gum base whenit is at a temperature of less than or equal to about 40° C.

Where the oral composition is in the form of a film, it can be formed byany number of conventional film forming processes, such as conventionalextrusion or solvent casting processes. For example, to prepare a filmby solvent casting, a film forming polymer is dissolved in a sufficientamount of a solvent which is compatible with the polymer. After asolution has been formed, a plasticizer can be added with stirring, andheat can be applied if necessary to aid dissolution, until a clear andhomogeneous solution has been formed, followed by the addition of theactive ingredients, including propolis extract, surface active agents,bulking agents, and any other ingredients such as flavors and sweetenersat a temperature of, for example, less than about 40° C. For ease ofuse, the dry film can be cut into pieces of suitable size and shape andpacked into a suitable container.

The oral compositions are applied to one or more oral surfaces in theoral cavity, and promote overall oral health, including inhibition ofplaque formation, gingivitis, periodontitis, halitosis, and the like. Incertain embodiments, the oral composition inhibits growth of variousoral bacteria and further provides at least one of: anti-inflammatoryactivity, biofilm disruption and/or anti-attachment activity. Thus,certain oral compositions provide multiple oral care benefitssimultaneously.

The present invention is further illustrated in the followingnon-limiting Example:

Example 1

A composition in accordance with the present invention was prepared,with the following constituents:

Component Weight % Water  40-70 Sorbitol  20-30 Hydrated Silica  10-20Methyl Vinyl Ether-Maleic Acid Copolymer  1-3 Sodium Lauryl Sulfate  1-3Flavor 0.5-3 Titanium Dioxide 0.1-3 Carrageenan 0.1-3 NaOH 0.1-3 SodiumSalts (sulfate, carbonate, chloride) 0.5-3 Triclosan 0.1-3 Sweetener0.1-2 Iron Oxide Hydrate 0.001-1  Propylene Glycol 0.001-1  SodiumFluoride 0.01-2  Alcohol 0.001-1  Propolis Extract 0.0001-3   Color0.0001-1  

We claim:
 1. An oral composition comprising: a propolis extract; an oralcare active compound chosen from: a cationic antibacterial agent, ananti-attachment agent, a biofilm disruption agent or ananti-inflammatory agent; and a source of fluoride ions.
 2. An oralcomposition according to claim 1, wherein the propolis extract ispresent in an amount of about 0.0001 to about 3%.
 3. An oral compositionaccording to claim 1, further comprising a polyhydric compound andwater.
 4. An oral composition according to claim 1, wherein the propolisextract comprises one or more active compounds derived from a propolissource in an amount of about 1 to about 5% by weight of the propolisextract.
 5. An oral composition according to claim 1, further comprisingan anionic polymeric linear polycarboxylate.
 6. An oral compositionaccording to claim 5, wherein the anionic polymeric linearpolycarboxylate is an anionic polymeric copolymer of methyl vinyl etherand maleic anhydride.
 7. An oral composition according to claim 1,wherein the oral care active compound is a cationic antibacterial agentchosen from benzethonium chloride, octenidine, hexetidine, hexamidine,cetyl pyridinium chloride, alexidine, N^(α)-acyl amino acid alkyl estersalts or mixtures thereof.
 8. An oral composition according to claim 7,wherein the oral care active compound is chosen from:N^(α)-cocoyl-L-arginine methyl ester, N^(α)-cocoyl-L-arginine ethylester, N^(α)-cocoyl-L-arginine propyl ester, N^(α)-stearoyl-L-argininemethyl ester, N^(α)-stearoyl-L-arginine ethyl ester, N^(α)-lauroylarginine ethyl ester, salts or mixtures thereof.
 9. An oral compositionaccording to claim 1, wherein the oral care active compound comprisesethyl lauroyl arginine ester hydrochloride (ELAH) or cetyl pyrindiniumchloride (CPC).
 10. An oral composition according to claim 1, whereinthe oral care active compound is chosen from: enzymes, histatin,furanone, and derivatives or mixtures thereof.
 11. An oral compositionaccording to claim 1, wherein the oral care active compound is chosenfrom: indomethicin, flurbiprofen, ketoprofen, ibuprofen, naproxen,meclofenamic acid, at least one free-B-ring flavonoid, a mixture of atleast one free-B-ring flavonoid and at least one flavan, an extract ofmagnolia, or mixtures thereof.
 12. An oral composition according toclaim 7, wherein the cationic antibacterial agent is present in anamount of about 0.001 to about 3% by weight.
 13. An oral compositionaccording to claim 1, wherein the source of fluoride ions is chosen fromsodium fluoride, sodium monofluorophosphate or mixtures thereof.
 14. Anoral composition according to claim 1 in a form of a mouthrinse,dentifrice, confectionary, medicament or film.
 15. An oral compositionaccording to claim 1, further comprising one or more carrier ingredientschosen from: surface active agents, viscosity modifiers, thickeners,humectants, diluents, pH modifying agents, emollients, moisturizers,mouth feel agents, sweetening agents, flavoring agents, solvent, water,colorants or preservatives.
 16. An oral composition according to claim1, wherein the oral care active compound is an anti-attachment agentpresent in an amount of about 0.001 to about 3% by weight.
 17. An oralcomposition according to claim 1, wherein the oral care active compoundis an anti-inflammatory agent comprising a non-steroidalanti-inflammatory drug (NSAID).
 18. An oral composition according toclaim 17, wherein the anti-inflammatory agent is chosen from:indomethicin, flurbiprofen, ketoprofen, ibuprofen, naproxen,meclofenamic acid, at least one free-B-ring flavonoid, a mixture of atleast one free-B-ring flavonoid and at least one flavan, an extract ofmagnolia or mixtures thereof.
 19. An oral composition according to claim17, wherein the anti-inflammatory agent is present in an amount of about0.001 to about 3% by weight.
 20. An oral composition according to claim1, wherein the oral care active compound comprises a biofilm disruptionagent chosen from: an enzyme, histatin, furanone or derivatives ormixtures thereof.
 21. An oral composition according to claim 20, whereinthe biofilm disruption agent comprises a protease enzyme.
 22. An oralcomposition according to claim 21, wherein the enzyme is papain orficin.
 23. An oral composition according to claim 20, wherein thebiofilm disruption agent is present in an amount of about 0.001 to about3% by weight.
 24. An oral composition according to claim 1, furthercomprising a carrier that comprises a surface active agent chosen from:a non-ionic surfactant, cationic surfactant, betaine surfactant,amphoteric surfactant or mixtures thereof.
 25. A method of preventingbacteria from forming a biofilm on an oral surface comprising the stepof applying to said oral surface a composition a composition comprisingan oral composition according to claim
 1. 26. A method of suppressing animmune system recognition of an antigen in an oral surface of a mammal,comprising administering a composition according to claim 1 to said oralsurface.
 27. A method of reducing an immune system response comprisingapplying a composition according to claim 17 to an oral surface.
 28. Themethod according to claim 27, wherein the immune system response isinflammation.
 29. A method of suppressing production of one or moremediators of inflammation on an oral surface, comprising applying anoral composition according to claim 1 to an oral surface.
 30. A methodof maintaining or increasing systemic health of a mammal comprisingapplying a composition according to claim 1 to an oral surface of saidmammal at least once a day for at least 2 days.
 31. A method of makingan oral composition comprising: admixing one or more carrier ingredientsto form a homogenous mixture; adding a fluoride ion source to themixture; adding at least one of: a cationic antibacterial agent, ananti-attachment agent, a biofilm disruption agent or ananti-inflammatory agent; and adding a propolis extract to thehomogeneous mixture at temperatures of less than or equal to about 40°C. to form the oral composition.
 32. A method according to claim 31,wherein the admixing of one or more carrier ingredients occurs at atemperature greater than or equal to about 40° C.
 33. A method accordingto claim 31, wherein the one or more carrier ingredients are chosenfrom: surface active agents, viscosity modifiers, thickeners,humectants, diluents, pH modifying agents, emollients, moisturizers,mouth feel agents, sweetening agents, flavoring agents, solvent, water,colorants, and preservatives.